ACTRN12605000625673招募中1 期
A Phase I, open label study of extended dosing with Patrin in combination with temozolomide in the treatment of patients with advanced melanoma. Part 1- to establish a dose for Part 2. Part 2 to test efficacy and safety of the dose established in Part 1.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Unresectable stage 3 /4 measurable (RECIST criteria), histologically proven cutaneous melanoma or unknown primary with melanoma metastases, without systemic treatment for metastatic disease.
排除标准
- •No exclusion criteria
研究者
相似试验
进行中（未招募）
不适用
A Phase I open label trial of continuous dosing with BIBW 2992 combined with paclitaxel and BIBW 2992 combined with paclitaxel and bevacizumab in patients with advanced solid tumours -EUCTR2006-005005-55-GBBoehringer Ingelheim Ltd
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioCystic fibrosis with the G551D mutationMedDRA version: 18.1 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003291-77-GBGalapagos NV26
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioEUCTR2015-003291-77-IEGalapagos NV32
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioEUCTR2015-003291-77-DEGalapagos NV32
进行中（未招募）
1 期
A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutatioCystic fibrosis with the G551D mutationMedDRA version: 19.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003291-77-CZGalapagos NV32